PMC:7600245 / 30069-30230
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T112 | 141-149 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T423 | 63-82 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T424 | 63-72 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T425 | 73-82 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T426 | 98-107 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T222 | 0-161 | Sentence | denotes | Furthermore, there is an evidence of some clinical benefit for lopinavir/ritonavir when used with ribavirin and/or INFs against MERS-CoV and SARS-CoV [88,93,94]. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 852 | 128-136 | Species | denotes | MERS-CoV | Tax:1335626 |
| 853 | 141-149 | Species | denotes | SARS-CoV | Tax:694009 |
| 861 | 63-82 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 862 | 98-107 | Chemical | denotes | ribavirin | MESH:D012254 |